February 2026 Product Updates

RX Products

Oral Semaglutide for Weight Management

Manufactured By: Novo Nordisk

The FDA has approved the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. The semaglutide (Wegovy; Novo Nordisk) pill offers patients a noninjectable alternative with weight loss efficacy comparable to that of the original injectable formulation, expanding access to GLP-1 therapy for millions of US adults living with obesity or overweight with at least 1 weight-related comorbidity. The FDA’s decision was supported by findings from the phase 3 OASIS 4 trial (NCT05564117), including results published in the New England Journal of Medicine. The estimated mean change in body weight from baseline to week 64 was −13.6% in the oral semaglutide group and −2.2% in the placebo group. Using a coformulated absorption enhancer, the oral formulation enabled consistent systemic exposure sufficient to drive weight-loss outcomes previously achievable only through injection. These results address long-standing adherence barriers for patients who are reluctant to initiate or continue injectable therapies. The safety profile of the semaglutide pill was consistent with that of other GLP-1 receptor agonists. The most commonly reported adverse events were gastrointestinal, including nausea, vomiting, diarrhea, and constipation, particularly during dose escalation.

For more information: wegovy.com

Mitapivat for Thalassemia

Manufactured By: Agios Pharmaceuticals

The FDA approved mitapivat (Aqvesme; Agios) for the treatment of anemia in adults with α- or β-thalassemia. This landmark decision marks the first medication indicated for both transfusion-dependent and non–transfusion-dependent forms of these rare, inherited blood disorders. Mitapivat is an oral pyruvate kinase activator that targets the underlying mechanisms that lead to shortened red blood cell lifespans. In the US, approximately 6000 adults are diagnosed with thalassemia, a condition characterized by genetic defects in the synthesis of globin chains. The FDA’s decision was bolstered by data from the phase 3 ENERGIZE (NCT04770753) and ENERGIZE-T (NCT04770779) trials. Despite its efficacy, mitapivat carries a boxed warning regarding hepatocellular injury. During clinical trials, some patients experienced liver injury, with 2 individuals requiring hospitalization. Consequently, the drug is available only through a Risk Evaluation and Mitigation Strategy program. Agios Pharmaceuticals expects the treatment to be available in the US by late January 2026.

For more information: aqvesme.com

OTC Product

Kourtney Kardashian Barker’s vitamin and supplement brand Lemme is expanding its portfolio with the launch of a new product focused on metabolic wellness, reinforcing the brand’s emphasis on approachable, lifestyle-driven health solutions. The newly debuted Lemme Burn Gummies are designed to support fat loss, body mass index reduction, and overall body composition, offering consumers a convenient and enjoyable way to incorporate metabolic support into their daily routines. Formulated with Morosil red orange extract, the gummies target key markers of metabolic health, while additional ingredients—including black ginger for energy and metabolic activity, chromium for macronutrient metabolism, and methylated vitamin B₁₂ and vitamin B₆ for cellular function and energy metabolism—round out the product’s functional profile. According to Kardashian Barker, the product reflects Lemme’s broader philosophy of sustainable wellness rather than quick fixes.

For more information: lemmelive.com

Generic Product

Retinal Diseases

Generic of: Lucentis

The FDA approved Nufymco (ranibizumab-leyk; Formycon AG, Zydus Lifesciences Limited), an interchangeable ranibizumab biosimilar referencing Lucentis (Genentech, Novartis). According to a news release from the manufacturer, Nufymco can be used interchangeably in all Lucentis indications, expanding retinal therapeutic options and improving access for patients who may have difficulty receiving or adhering to treatment. Reference ranibizumab is a humanized, recombinant monoclonal antibody fragment that targets VEGF to manage and treat retinal diseases. This inhibits the interaction of VEGF-A—which plays a significant role in vascular leak and angiogenesis in the development of retinal diseases—with its receptors on endothelial cells, preventing endothelial proliferation, vascular permeability, and neovascularization. Adverse effects associated with ranibizumab use include conjunctival hemorrhage, eye pain, vitreous floaters, and both short- and long-term increases in ocular pressure.
This action grants Nufymco interchangeability for the FDA-approved indications for Lucentis, including the treatment of patients with age-related neovascular (wet) macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema due to retinal vein occlusion, and myopic choroidal neovascularization.

For more information: formycon.com